Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients

Molecular Therapy

Volumn 21, Issue 6, 2013, Pages 1212-1223

  Liikanen, Ilkka ^a   Ahtiainen, Laura ^a   Hirvinen, Mari L ^a   Bramante, Simona ^a   Cerullo, Vincenzo ^a   Nokisalmi, Petri ^a   Hemminki, Otto ^a   Diaconu, Iulia ^a   Pesonen, Sari ^a   Koski, Anniina ^a   Kangasniemi, Lotta ^b   Pesonen, Saila K ^a   Oksanen, Minna ^a   Laasonen, Leena ^c   Partanen, Kaarina ^c   Joensuu, Timo ^c   Zhao, Fang ^a   Kanerva, Anna ^a,d   Hemminki, Akseli ^a,b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b Oncos Therapeutics Inc   (Finland)

^c International Comprehensive Cancer Center Docrates   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CALRETICULIN; CYCLOPHOSPHAMIDE; CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 5 3 D24 GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PERFOSFAMIDE; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTICLE; AUTOPHAGY; BACKACHE; BILE DUCT CARCINOMA; BLOATING; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CELL DEATH; CELL KILLING; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; COLON CANCER; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; CYTOPATHOGENIC EFFECT; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; DYSPNEA; EDEMA; ENDOMETRIUM SARCOMA; ENZYME BLOOD LEVEL; FATIGUE; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEAD AND NECK CANCER; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; ILEUS; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE PAIN; INTERNATIONAL NORMALIZED RATIO; INTRACELLULAR SIGNALING; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG ADENOCARCINOMA; LYMPHOCYTOPENIA; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MESOTHELIOMA; MONOTHERAPY; MOUSE; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; SARCOMA; SIDE EFFECT; SWEATING; SWELLING; SYNOVIAL SARCOMA; T CELL DEPLETION; T LYMPHOCYTE; THORAX PAIN; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE;

EID: 84878530852     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.51     Document Type: Article

References (50)

1. Ito, H, Aoki, H, Kühnel, F, Kondo, Y, Kubicka, S, Wirth, T et al. (2006). Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. J Natl Cancer Inst 98: 625-636.
2. Jiang, H, White, EJ, Ríos-Vicil, CI, Xu, J, Gomez-Manzano, C and Fueyo, J (2011). Human adenovirus type 5 induces cell lysis through autophagy and autophagy-triggered caspase activity. J Virol 85: 4720-4729.
3. Chen, N and Karantza, V (2011). Autophagy as a therapeutic target in cancer. Cancer Biol Ther 11: 157-168.
4. Michaud, M, Martins, I, Sukkurwala, AQ, Adjemian, S, Ma, Y, Pellegatti, P et al. (2011). Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 334: 1573-1577.
5. Martins, I, Michaud, M, Sukkurwala, AQ, Adjemian, S, Ma, Y, Shen, S et al. (2012). Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy 8: 413-415.
6. Hannani, D, Sistigu, A, Kepp, O, Galluzzi, L, Kroemer, G and Zitvogel, L (2011). Prerequisites for the antitumor vaccine-like effect of chemotherapy and radiotherapy. Cancer J 17: 351-358.
7. Rodriguez-Rocha, H, Gomez-Gutierrez, JG, Garcia-Garcia, A, Rao, XM, Chen, L, McMasters, KM et al. (2011). Adenoviruses induce autophagy to promote virus replication and oncolysis. Virology 416: 9-15.
8. Kanzawa, T, Germano, IM, Komata, T, Ito, H, Kondo, Y and Kondo, S (2004). Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 11: 448-457.
9. Gao, S, Yang, XJ, Zhang, WG, Ji, YW and Pan, Q (2009). Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro. Chin Med J 122: 1260-1266.
10. Palumbo, S, Pirtoli, L, Tini, P, Cevenini, G, Calderaro, F, Toscano, M et al. (2012). Different involvement of autophagy in human malignant glioma cell lines undergoing irradiation and temozolomide combined treatments. J Cell Biochem 113: 2308-2318.
11. Sotelo, J, Briceño, E and López-González, MA (2006). Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 144: 337-343.
12. Hwu, WJ, Krown, SE, Menell, JH, Panageas, KS, Merrell, J, Lamb, LA et al. (2003). Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. J Clin Oncol 21: 3351-3356.
13. Chang, SM, Lamborn, KR, Malec, M, Larson, D, Wara, W, Sneed, P et al. (2004). Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 60: 353-357.
14. Zou, W (2006). Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307.
15. Ghiringhelli, F, Menard, C, Puig, PE, Ladoire, S, Roux, S, Martin, F et al. (2007). Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56: 641-648.
16. Cerullo, V, Diaconu, I, Kangasniemi, L, Rajecki, M, Escutenaire, S, Koski, A et al. (2011). Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 19: 1737-1746.
17. Chou, TC (2010). Drug combination studies and their synergy quantifcation using the Chou-Talalay method. Cancer Res 70: 440-446.
18. Kepp, O, Galluzzi, L, Martins, I, Schlemmer, F, Adjemian, S, Michaud, M et al. (2011). Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 30: 61-69.
19. Kanerva, A, Nokisalmi, P, Tähtinen, S, Koski, A, Kangasniemi, L, Diaconu, I et al. (2012). Serial treatment with oncolytic adenovirus results in redistribution of T-cell subsets in humans and mice. Mol Ther 20: Supplement 1.
20. Brahmer, JR, Drake, CG, Wollner, I, Powderly, JD, Picus, J, Sharfman, WH et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
21. Galanis, E, Okuno, SH, Nascimento, AG, Lewis, BD, Lee, RA, Oliveira, AM et al. (2005). Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437-445.
22. Kirn, D (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 8: 89-98.
23. Cheong, SC, Wang, Y, Meng, JH, Hill, R, Sweeney, K, Kirn, D et al. (2008). E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 15: 40-50.
24. Raki, M, Kanerva, A, Ristimaki, A, Desmond, RA, Chen, DT, Ranki, T et al. (2005). Combination of gemcitabine and Ad5/3-Delta24, a tropism modifed conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12: 1198-1205.
25. Khuri, FR, Nemunaitis, J, Ganly, I, Arseneau, J, Tannock, IF, Romel, L et al. (2000). a controlled trial of intratumoral ONYX-015, a selectively- replicating adenovirus, in combination with cisplatin and 5-fuorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885.
26. Ottolino-Perry, K, Diallo, JS, Lichty, BD, Bell, JC and McCart, JA (2010). Intelligent design: combination therapy with oncolytic viruses. Mol Ther 18: 251-263.
27. Alonso, MM, Gomez-Manzano, C, Jiang, H, Bekele, NB, Piao, Y, Yung, WK et al. (2007). Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo. Cancer Gene Ther 14: 756-761.
28. Green, DR, Ferguson, T, Zitvogel, L and Kroemer, G (2009). Immunogenic and tolerogenic cell death. Nat Rev Immunol 9: 353-363.
29. Ulasov, IV, Sonabend, AM, Nandi, S, Khramtsov, A, Han, Y and Lesniak, MS (2009). Combination of adenoviral virotherapy and temozolomide chemotherapy eradicates malignant glioma through autophagic and apoptotic cell death in vivo. Br J Cancer 100: 1154-1164.
30. Scaffdi, P, Misteli, T and Bianchi, ME (2002). Release of chromatin protein HMGB1 by necrotic cells triggers infammation. Nature 418: 191-195.
31. Bianchi, ME and Manfredi, AA (2007). High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 220: 35-46.
32. Appledorn, DM, Patial, S, McBride, A, Godbehere, S, Van Rooijen, N, Parameswaran, N et al. (2008). Adenovirus vector-induced innate infammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol 181: 2134-2144.
33. Cerullo, V, Seiler, M P, Mane, V, Brunetti-Pierri, N, Clarke, C, Bertin, TK et al. (2007). Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15: 378-385.
34. Schjetne, KW, Thompson, KM, Nilsen, N, Flo, TH, Fleckenstein, B, Iversen, JG et al. (2003). Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4+ T cells and could be an effcient vaccine target. J Immunol 171: 32-36.
35. Jounai, N, Kobiyama, K and Takeshita, F (2012). Intracellular infammatory sensors for foreign invaders and substances of self-origin. Adv Exp Med Biol 738: 60-78.
36. Koski, A, Raki, M, Nokisalmi, P, Liikanen, I, Kangasniemi, L, Joensuu, T et al. (2012). Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 20: 221-229.
37. Nokisalmi, P, Pesonen, S, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 16: 3035-3043.
38. Pesonen, S, Diaconu, I, Cerullo, V, Escutenaire, S, Raki, M, Kangasniemi, L et al. (2012). Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 130: 1937-1947.
39. Pesonen, S, Nokisalmi, P, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 17: 892-904.
40. Koski, A, Kangasniemi, L, Escutenaire, S, Pesonen, S, Cerullo, V, Diaconu, I et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18: 1874-1884.
41. Cerullo, V, Pesonen, S, Diaconu, I, Escutenaire, S, Arstila, P T, Ugolini, M et al. (2010). Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70: 4297-4309.
42. Diaconu, I, Cerullo, V, Hirvinen, ML, Escutenaire, S, Ugolini, M, Pesonen, SK et al. (2012). Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res 72: 2327-2338.
43. Pesonen, S, Diaconu, I, Kangasniemi, L, Ranki, T, Kanerva, A, Pesonen, SK et al. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 72: 1621-1631.
44. Hemminki, O, Bauerschmitz, G, Hemmi, S, Lavilla-Alonso, S, Diaconu, I, Guse, K et al. (2011). Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 18: 288-296.
45. Kanerva, A, Wang, M, Bauerschmitz, GJ, Lam, JT, Desmond, RA, Bhoola, SM et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fber-modifed adenoviruses. Mol Ther 5: 695-704.
46. Krasnykh, V, Belousova, N, Korokhov, N, Mikheeva, G and Curiel, DT (2001). Genetic targeting of an adenovirus vector via replacement of the fber protein with the phage T4 fbritin. J Virol 75: 4176-4183.
47. Kanerva, A, Mikheeva, GV, Krasnykh, V, Coolidge, CJ, Lam, JT, Mahasreshti, PJ et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer effciency to ovarian cancer cells. Clin Cancer Res 8: 275-280.
48. Fleischli, C, Sirena, D, Lesage, G, Havenga, MJ, Cattaneo, R, Greber, UF et al. (2007). Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol 88(Pt 11): 2925-2934.
49. Eisenhauer, EA, Therasse, P, Bogaerts, J, Schwartz, LH, Sargent, D, Ford, R et al. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
50. Escutenaire, S, Cerullo, V, Diaconu, I, Ahtiainen, L, Hannuksela, P, Oksanen, M et al. (2011). In vivo and in vitro distribution of type 5 and fber-modifed oncolytic adenoviruses in human blood compartments. Ann Med 43: 151-163.